{"id":"https://openalex.org/W2890639320","doi":"https://doi.org/10.1200/jco.2018.36.15_suppl.4065","title":"Investigation of PD-L1 expression and response to pembrolizumab (pembro) in gastric cancer (GC) and cervical cancer (CC) using combined positive score (CPS) and tumor proportion score (TPS).","display_name":"Investigation of PD-L1 expression and response to pembrolizumab (pembro) in gastric cancer (GC) and cervical cancer (CC) using combined positive score (CPS) and tumor proportion score (TPS).","publication_year":2018,"publication_date":"2018-05-20","ids":{"openalex":"https://openalex.org/W2890639320","doi":"https://doi.org/10.1200/jco.2018.36.15_suppl.4065","mag":"2890639320"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2018.36.15_suppl.4065","doi":"https://doi.org/10.1200/jco.2018.36.15_suppl.4065","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2018.36.15_suppl.4065","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5057130039","display_name":"Karina Kulangara","orcid":"https://orcid.org/0000-0002-1852-3534","observed_orcids":["https://orcid.org/0000-0002-1852-3534"]},"institutions":[{"id":"https://openalex.org/I138285227","display_name":"Agilent Technologies (United States)","ror":"https://ror.org/02tryst02","country_code":"US","type":"company","lineage":["https://openalex.org/I138285227"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Karina Kulangara","raw_affiliation_strings":["Dako North America, Agilent Technologies, Carpinteria, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dako North America, Agilent Technologies, Carpinteria, CA;","institution_ids":["https://openalex.org/I138285227"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112562867","display_name":"Lindsay Guerrero","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I138285227","display_name":"Agilent Technologies (United States)","ror":"https://ror.org/02tryst02","country_code":"US","type":"company","lineage":["https://openalex.org/I138285227"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lindsay Guerrero","raw_affiliation_strings":["Dako North America, Agilent Technologies, Carpinteria, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dako North America, Agilent Technologies, Carpinteria, CA;","institution_ids":["https://openalex.org/I138285227"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039385175","display_name":"Alexander Posch","orcid":"https://orcid.org/0000-0002-5846-5367","observed_orcids":["https://orcid.org/0000-0002-5846-5367"]},"institutions":[{"id":"https://openalex.org/I138285227","display_name":"Agilent Technologies (United States)","ror":"https://ror.org/02tryst02","country_code":"US","type":"company","lineage":["https://openalex.org/I138285227"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alex Posch","raw_affiliation_strings":["Dako North America, Agilent Technologies, Carpinteria, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dako North America, Agilent Technologies, Carpinteria, CA;","institution_ids":["https://openalex.org/I138285227"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Scott Boyer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I138285227","display_name":"Agilent Technologies (United States)","ror":"https://ror.org/02tryst02","country_code":"US","type":"company","lineage":["https://openalex.org/I138285227"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Scott Boyer","raw_affiliation_strings":["Dako North America, Agilent Technologies, Carpinteria, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dako North America, Agilent Technologies, Carpinteria, CA;","institution_ids":["https://openalex.org/I138285227"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033449928","display_name":"Debra Ann Hanks","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I138285227","display_name":"Agilent Technologies (United States)","ror":"https://ror.org/02tryst02","country_code":"US","type":"company","lineage":["https://openalex.org/I138285227"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Debra Ann Hanks","raw_affiliation_strings":["Dako North America, Agilent Technologies, Carpinteria, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dako North America, Agilent Technologies, Carpinteria, CA;","institution_ids":["https://openalex.org/I138285227"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013552756","display_name":"Josette F. Carnahan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I138285227","display_name":"Agilent Technologies (United States)","ror":"https://ror.org/02tryst02","country_code":"US","type":"company","lineage":["https://openalex.org/I138285227"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Josette Carnahan","raw_affiliation_strings":["Dako North America, Agilent Technologies, Carpinteria, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dako North America, Agilent Technologies, Carpinteria, CA;","institution_ids":["https://openalex.org/I138285227"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064264391","display_name":"Jiangdian Wang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jiangdian Wang","raw_affiliation_strings":["Merck & Co., Inc., Kenilworth, NJ;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc., Kenilworth, NJ;","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061867713","display_name":"Jared K. Lunceford","orcid":"https://orcid.org/0000-0001-8120-2277","observed_orcids":["https://orcid.org/0000-0001-8120-2277"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jared Lunceford","raw_affiliation_strings":["Merck & Co., Inc., Kenilworth, NJ;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc., Kenilworth, NJ;","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110070089","display_name":"Mary J. Savage","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mary Savage","raw_affiliation_strings":["Merck & Co., Inc., Kenilworth, NJ;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc., Kenilworth, NJ;","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071580103","display_name":"Matthew John Marton","orcid":"https://orcid.org/0000-0003-2080-7912","observed_orcids":["https://orcid.org/0000-0003-2080-7912"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Matthew John Marton","raw_affiliation_strings":["Merck & Co., Inc., Kenilworth, NJ;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc., Kenilworth, NJ;","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112320058","display_name":"Scott Knowles Pruitt","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Scott K. Pruitt","raw_affiliation_strings":["Merck & Co., Inc., Kenilworth, NJ;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc., Kenilworth, NJ;","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110575098","display_name":"Jonathan Wes Juco","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jonathan Wes Juco","raw_affiliation_strings":["Merck & Co., Inc., Kenilworth, NJ;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc., Kenilworth, NJ;","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5062557677","display_name":"Kenneth Emancipator","orcid":"https://orcid.org/0000-0002-6629-4430","observed_orcids":["https://orcid.org/0000-0002-6629-4430"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kenneth Emancipator","raw_affiliation_strings":["Merck & Co., Inc., Kenilworth, NJ;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc., Kenilworth, NJ;","institution_ids":["https://openalex.org/I1285764155"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":23,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"36","issue":"15_suppl","first_page":"4065","last_page":"4065"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10696","display_name":"Gastric Cancer Management and Outcomes","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11297","display_name":"Ferroptosis and cancer prognosis","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pd-l1-expression","display_name":"PD-L1 expression","score":0.9829999804496765},{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":0.9919999837875366},{"id":"https://openalex.org/keywords/gastric-cancer","display_name":"gastric cancer","score":0.9750000238418579},{"id":"https://openalex.org/keywords/cervical-cancer","display_name":"cervical cancer","score":1.0},{"id":"https://openalex.org/keywords/combined-positive-score","display_name":"combined positive score","score":0.8799999952316284},{"id":"https://openalex.org/keywords/tumor-proportion-score","display_name":"tumor proportion score","score":0.9980000257492065},{"id":"https://openalex.org/keywords/predictive-biomarkers","display_name":"predictive biomarkers","score":0.9330000281333923},{"id":"https://openalex.org/keywords/interobserver-agreement","display_name":"interobserver agreement","score":0.6110000014305115},{"id":"https://openalex.org/keywords/keynote-158","display_name":"KEYNOTE-158","score":0.9990000128746033},{"id":"https://openalex.org/keywords/tumor-infiltrating-lymphocytes","display_name":"tumor-infiltrating lymphocytes","score":0.5580000281333923},{"id":"https://openalex.org/keywords/tumor-infiltrating-macrophages","display_name":"tumor-infiltrating macrophages","score":0.843999981880188},{"id":"https://openalex.org/keywords/tumor-immune-microenvironment","display_name":"tumor immune microenvironment","score":0.375}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.753669023513794},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.6549145579338074},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.612760066986084},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.545520007610321},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.48541054129600525},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.45541927218437195},{"id":"https://openalex.org/C2989005","wikidata":"https://www.wikidata.org/wiki/Q214963","display_name":"Nuclear medicine","level":1,"score":0.3357146680355072},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.26373106241226196}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2018.36.15_suppl.4065","doi":"https://doi.org/10.1200/jco.2018.36.15_suppl.4065","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2018.36.15_suppl.4065","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.98580002784729}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.8299999833106995}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2970228237","https://openalex.org/W3094344660","https://openalex.org/W2998841267","https://openalex.org/W4317653603","https://openalex.org/W3107686376","https://openalex.org/W2978312763","https://openalex.org/W6921116155","https://openalex.org/W3132958914","https://openalex.org/W7204589887","https://openalex.org/W2760330862"],"abstract_inverted_index":{"4065":[0],"Background:":[1],"TPS,":[2],"the":[3,50,95,116,127,168],"percentage":[4],"of":[5,53,94,114,118,130,157,210,262,281],"viable":[6,131],"tumor":[7,132],"cells":[8,120],"with":[9,60,66,75,176,194],"partial":[10],"or":[11,81],"complete":[12],"membrane":[13],"staining":[14],"at":[15,155],"any":[16],"intensity,":[17],"has":[18,43],"been":[19],"invaluable":[20],"for":[21,87,151,213,291],"assessing":[22],"PD-L1":[23,88,96,282,297,299],"expression":[24,89],"in":[25,64,167,185,202,226,239,256,264],"non\u2013small":[26],"cell":[27],"lung":[28],"cancer":[29,302,319],"(NSCLC)":[30],"and":[31,55,57,68,146,153,161,198,205,220,228,233,258,274,276],"identifying":[32],"patients":[33],"(pts)":[34],"likely":[35],"to":[36,38,62,171,189],"respond":[37],"anti-PD\u20131/PD-L1":[39],"therapy.":[40],"However,":[41],"TPS":[42,54,154,182,199,255],"limited":[44],"utility":[45],"beyond":[46,266],"NSCLC.":[47],"We":[48],"investigated":[49],"predictive":[51,143,148],"value":[52,144,149],"CPS":[56,152,177,195,214,242,263],"their":[58],"association":[59],"response":[61,188],"pembro":[63,172,190],"pts":[65,74],"GC":[67,78,227,257],"CC.":[69,203,240,259],"Methods:":[70],"Tumor":[71,292],"samples":[72],"from":[73],"previously":[76],"treated":[77],"(KEYNOTE-059,":[79],"NCT02335411)":[80],"CC":[82],"(KEYNOTE-158,":[83],"NCT02628067)":[84],"were":[85,215],"analyzed":[86],"per":[90,106],"an":[91],"investigational-use-only-labeled":[92],"version":[93],"IHC":[97],"22C3":[98],"pharmDx":[99],"assay":[100],"(Agilent":[101],"Technologies).":[102],"Response":[103,170,293],"was":[104,137,173,191],"assessed":[105],"RECIST":[107],"v1.1":[108],"by":[109,126,135],"independent":[110],"review.":[111],"External":[112],"reproducibility":[113,212],"CPS,":[115],"number":[117,129],"PD-L1\u2013staining":[119],"(tumor":[121],"cells,":[122,133],"lymphocytes,":[123],"macrophages)":[124],"divided":[125],"total":[128],"multiplied":[134],"100,":[136],"assessed.":[138],"Results:":[139],"Response,":[140],"prevalence,":[141],"positive":[142],"(PPV),":[145],"negative":[147],"(NPV)":[150],"cutoffs":[156],"1":[158],"(TPS1,":[159],"CPS1)":[160],"10":[162],"(TPS10,":[163],"CPS10)":[164],"are":[165],"shown":[166],"table.":[169],"significantly":[174,192],"associated":[175,193],"(P=":[178,183,196,200],"0.002)":[179],"but":[180],"not":[181],"0.224)":[184],"GC,":[186],"whereas":[187],"0.008)":[197],"0.023)":[201],"Intersite":[204],"interobserver":[206],"overall":[207],"agreement":[208],"assessments":[209],"external":[211],"92.0%":[216],"(95%":[217,222,230,235],"CI,":[218,223,231,236],"87.4-96.3)":[219],"96.6%":[221],"94.0-98.7),":[224],"respectively,":[225,238],"95.0%":[229],"90.3-99.2)":[232],"99.7%":[234],"99.7-100.0),":[237],"Conclusions:":[241],"is":[243,268],"a":[244],"robust,":[245],"reproducible":[246],"scoring":[247],"method":[248],"that":[249],"identified":[250],"more":[251],"responders":[252],"than":[253],"did":[254],"Further":[260],"investigation":[261],"cancers":[265],"NSCLC":[267],"warranted.":[269],"Clinical":[270],"trial":[271],"information:":[272],"NCT02335411":[273],"NCT02628067.Scoring":[275],"Cutoff":[277],"Responders/Total":[278],"n/N":[279],"Prevalence":[280],"Expression,":[283],"%":[284,286,288],"PPV,":[285],"NPV,":[287],"Odds":[289],"ratio":[290],"All":[294],"Patients,":[295],"N":[296],"Positive":[298],"Negative":[300],"Gastric":[301],"CPS1":[303,320],"257":[304],"24/148":[305],"7/109":[306],"58":[307],"16":[308,315,325],"94":[309,340],"2.8":[310],"TPS1":[311,328],"5/32":[312],"26/225":[313],"12":[314],"88":[316],"1.4":[317],"Cervical":[318],"96":[321],"13/81":[322],"0/15":[323],"84":[324],"100":[326],"\u221e":[327],"10/50":[329],"3/46":[330],"52":[331],"20":[332],"93":[333],"3.6":[334],"CPS10":[335],"10/45":[336],"3/51":[337],"47":[338],"22":[339],"4.6":[341],"TPS10":[342],"6/26":[343],"7/70":[344],"27":[345],"23":[346],"90":[347],"2.7":[348]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":5},{"year":2023,"cited_by_count":4},{"year":2022,"cited_by_count":5},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":1},{"year":2018,"cited_by_count":1}],"updated_date":"2026-10-01T08:54:57.152042","created_date":"2018-09-27T00:00:00"}